Sentences with phrase «immune checkpoint inhibitor antibody»

Not exact matches

«We wanted to utilize platelets» intrinsic tendencies to accumulate at wounds and to interact with circulating tumor cells, for targeted delivery of immune checkpoint inhibitors» said Gu, «Interestingly, we found the antibody can be promoted to release from activated platelets in the surgical site, due to generation of small platelet - derived microparticles upon the platelet activation.

The cancer cells» defense strategy can be overcome by immune checkpoint inhibitor agents, including anti-PD-1 / PD - L1 antibodies, several kinds of which have received fast - track approval from the U.S. Food and Drug Administration (FDA).

Known as a checkpoint inhibitor, tremelimumab is an investigational monoclonal antibody that «cuts the brakes» of the immune system by targeting cytotoxic T - lymphocyte antigen 4 (CTLA - 4), a protein that can switch off a patient's immune response.

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

Checkpoint inhibitors are monoclonal antibodies that target certain proteins that downregulate the immune system, such as programmed cell death protein 1 (PD - 1), programmed death - ligand 1 (PD - L1) and cytotoxic T - lymphocyte antigen 4 (CTLA - 4).

Current immunotherapies for ovarian cancer fall into six broad categories: monoclonal antibodies; checkpoint inhibitors and immune modulators; therapeutic vaccines; adoptive T cell transfer; oncolytic viruses; and adjuvant immunotherapies.

These treatments can be broken into four categories: monoclonal antibodies, checkpoint inhibitors and immune modulators, cancer vaccines, and adoptive cell therapy.

These treatments can be broken into 5 main categories: checkpoint inhibitors / immune modulators, adoptive cell transfer, monoclonal antibodies, therapeutic vaccines, and cytokines.

Current immunotherapies for colorectal cancer fall into seven broad categories: checkpoint inhibitors and immune modulators, monoclonal antibodies, therapeutic vaccines, adoptive cell therapy, oncolytic virus therapy, adjuvant immunotherapies, and cytokines.

To combat the nation's third deadliest cancer, the phase 1b / 2 open - label study will explore the combination of standard chemotherapy and two immunotherapy agents: an anti-PD-1 checkpoint inhibitor and a novel antibody targeting CD40, a protein that when activated can drive the immune system to attack tumors.

Gowans MF et al. (2018) Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.

They fall into six broad categories: checkpoint inhibitors and immune modulators, cancer vaccines, adoptive cell therapy, monoclonal antibodies, cytokines, and adjuvant immunotherapies.

Additionally, the greater the number of these trunk neoantigens, the more likely the patient will respond to immune checkpoint inhibitor therapy, an antibody - based intervention that unleashes T cells to attack tumors.